Keros Therapeutics (KROS) Liabilities and Shareholders Equity (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $338.0 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 45.12% year-over-year to $338.0 million; the trailing twelve-month figure through Dec 2025 stood at $2.6 billion (up 22.78% YoY), and the FY2025 full-year result was $338.0 million, down 45.12% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $338.0 million, down from $742.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $784.6 million in Q1 2025 and bottomed at $226.7 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $347.2 million (2023), against an average of $410.2 million.
• The widest annual swing landed in 2021, when Liabilities and Shareholders Equity surged 325.35%; it then slumped 45.12% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $255.3 million in 2021, then gained by 20.19% to $306.8 million in 2022, then climbed by 20.62% to $370.0 million in 2023, then surged by 66.44% to $615.9 million in 2024, then plunged by 45.12% to $338.0 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $338.0 million (Q4 2025), $742.8 million (Q3 2025), and $757.2 million (Q2 2025), per Business Quant data.

Peer Comparison